SCHEMBL11945634

SCHEMBL11945634

CC1(COc2c(N3CCN(S(=O)(=O)Cc4cc(S(N)(=O)=O)ccc4N)CC3)cnn(-c3cc(F)cc(F)c3)c2=O)CC1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 8/20 0.37
▸ CA1 P00915 8/20 0.37
▸ CA2 P00918 8/20 0.37
▸ CA9 Q16790 8/20 0.37
▸ POLB P06746 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ PPARG P37231 1/20 0.37
▸ NCOA2 Q15596 1/20 0.37
▸ NCOA1 Q15788 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ NCOA3 Q9Y6Q9 1/20 0.37
▸ MAPT P10636 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.34
▸ DCTPP1 Q9H773 1/20 0.31
▸ PARG Q86W56 1/20 0.31
▸ MMP13 P45452 1/20 0.31
▸ CXCR3 P49682 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11944574 0.93 MAPT (0.38) CA12CA1CA2CA9POLB
SCHEMBL11945336 0.90 MAPT (0.41) CA12CA1CA2CA9POLB
SCHEMBL11946268 0.87 MAPT (0.38) CA12CA1CA2CA9POLB
SCHEMBL11945633 0.87 USP7 (0.36) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11944458 0.86 MAPT (0.36) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11945632 0.86 MAPT (0.38) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11945630 0.86 MAPT (0.37) CA12CA1CA2CA9POLB
SCHEMBL11944396 0.86 MAPT (0.38) CA12CA1CA2CA9POLB
SCHEMBL4136489 0.85 MAPT (0.36) CA12CA1CA2CA9POLB
SCHEMBL11945642 0.85 MAPT (0.41) CA12CA1CA2CA9POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA CA12 4603/4885CA1 4563/4885CA2 3206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback